Unusually aggressive type 1 gastric carcinoid: A case report with a review of the literature

Matilde Pia Spampatti, Sara Massironi, Roberta Elisa Rossi, Dario Conte, Valentina Sciola, Clorinda Ciafardini, Stefano Ferrero, Lucia Lodi, Maddalena Peracchi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Gastric carcinoids are rare tumors of the stomach. Gastric carcinoid type 1 is associated with chronic atrophic gastritis, and because of a low metastatic potential, is the most benign type. Death from metastatic disease has been reported in only three patients in a review including 724 cases. The present report refers to a 60-year-old man who was affected by type 2 diabetes mellitus and pernicious anemia and died from metastatic gastric carcinoid type 1. In 1998, a well-differentiated 1.2 cm gastric neuroendocrine tumor, immunoreactive for chromogranin A, with a Ki-67 index less than 2% and with infiltration to the submucosal layer was diagnosed and enucleated. In 2002, a new well-differentiated gastric endocrine tumor 6 mm in size with a Ki-67 of approximately 2% was detected, and endoscopic ultrasound confirmed it to be limited to the submucosal layer. The patient refused antrectomy and started long-acting somatostatin analog (lanreotide) in 2005 when the Ki-67 index was 7%, but he stopped the treatment after 4 months. In 2007, despite previous endoscopic stability, endoscopic ultrasound showed an infiltrating gastric lesion of 7 cm. At surgery, the disease appeared to be extended to the liver and to the peritoneum (well-differentiated endocrine carcinoma, Ki-67 40%) with both hepatic and massive peritoneal metastases. A regimen of somatostatin analog was soon restarted; however, the disease continued to spread, and the patient died 6 months later. Overall, despite their generally benign course, type 1 gastric carcinoids may have malignant potential, a finding that should be considered when planning the medical workup of these patients.

Original languageEnglish
Pages (from-to)589-593
Number of pages5
JournalEuropean Journal of Gastroenterology and Hepatology
Volume24
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Carcinoid Tumor
Stomach
Somatostatin
Atrophic Gastritis
Chromogranin A
Pernicious Anemia
Neuroendocrine Tumors
Liver
Peritoneum
Type 2 Diabetes Mellitus
Neoplasm Metastasis
Carcinoma

Keywords

  • atrophic gastritis
  • carcinoid metastases
  • gastric carcinoids
  • neuroendocrine tumors
  • octreotide test

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Unusually aggressive type 1 gastric carcinoid : A case report with a review of the literature. / Spampatti, Matilde Pia; Massironi, Sara; Rossi, Roberta Elisa; Conte, Dario; Sciola, Valentina; Ciafardini, Clorinda; Ferrero, Stefano; Lodi, Lucia; Peracchi, Maddalena.

In: European Journal of Gastroenterology and Hepatology, Vol. 24, No. 5, 05.2012, p. 589-593.

Research output: Contribution to journalArticle

Spampatti, Matilde Pia ; Massironi, Sara ; Rossi, Roberta Elisa ; Conte, Dario ; Sciola, Valentina ; Ciafardini, Clorinda ; Ferrero, Stefano ; Lodi, Lucia ; Peracchi, Maddalena. / Unusually aggressive type 1 gastric carcinoid : A case report with a review of the literature. In: European Journal of Gastroenterology and Hepatology. 2012 ; Vol. 24, No. 5. pp. 589-593.
@article{c7dd2825973c41d1a780a1114ca54c60,
title = "Unusually aggressive type 1 gastric carcinoid: A case report with a review of the literature",
abstract = "Gastric carcinoids are rare tumors of the stomach. Gastric carcinoid type 1 is associated with chronic atrophic gastritis, and because of a low metastatic potential, is the most benign type. Death from metastatic disease has been reported in only three patients in a review including 724 cases. The present report refers to a 60-year-old man who was affected by type 2 diabetes mellitus and pernicious anemia and died from metastatic gastric carcinoid type 1. In 1998, a well-differentiated 1.2 cm gastric neuroendocrine tumor, immunoreactive for chromogranin A, with a Ki-67 index less than 2{\%} and with infiltration to the submucosal layer was diagnosed and enucleated. In 2002, a new well-differentiated gastric endocrine tumor 6 mm in size with a Ki-67 of approximately 2{\%} was detected, and endoscopic ultrasound confirmed it to be limited to the submucosal layer. The patient refused antrectomy and started long-acting somatostatin analog (lanreotide) in 2005 when the Ki-67 index was 7{\%}, but he stopped the treatment after 4 months. In 2007, despite previous endoscopic stability, endoscopic ultrasound showed an infiltrating gastric lesion of 7 cm. At surgery, the disease appeared to be extended to the liver and to the peritoneum (well-differentiated endocrine carcinoma, Ki-67 40{\%}) with both hepatic and massive peritoneal metastases. A regimen of somatostatin analog was soon restarted; however, the disease continued to spread, and the patient died 6 months later. Overall, despite their generally benign course, type 1 gastric carcinoids may have malignant potential, a finding that should be considered when planning the medical workup of these patients.",
keywords = "atrophic gastritis, carcinoid metastases, gastric carcinoids, neuroendocrine tumors, octreotide test",
author = "Spampatti, {Matilde Pia} and Sara Massironi and Rossi, {Roberta Elisa} and Dario Conte and Valentina Sciola and Clorinda Ciafardini and Stefano Ferrero and Lucia Lodi and Maddalena Peracchi",
year = "2012",
month = "5",
doi = "10.1097/MEG.0b013e328350fae8",
language = "English",
volume = "24",
pages = "589--593",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Unusually aggressive type 1 gastric carcinoid

T2 - A case report with a review of the literature

AU - Spampatti, Matilde Pia

AU - Massironi, Sara

AU - Rossi, Roberta Elisa

AU - Conte, Dario

AU - Sciola, Valentina

AU - Ciafardini, Clorinda

AU - Ferrero, Stefano

AU - Lodi, Lucia

AU - Peracchi, Maddalena

PY - 2012/5

Y1 - 2012/5

N2 - Gastric carcinoids are rare tumors of the stomach. Gastric carcinoid type 1 is associated with chronic atrophic gastritis, and because of a low metastatic potential, is the most benign type. Death from metastatic disease has been reported in only three patients in a review including 724 cases. The present report refers to a 60-year-old man who was affected by type 2 diabetes mellitus and pernicious anemia and died from metastatic gastric carcinoid type 1. In 1998, a well-differentiated 1.2 cm gastric neuroendocrine tumor, immunoreactive for chromogranin A, with a Ki-67 index less than 2% and with infiltration to the submucosal layer was diagnosed and enucleated. In 2002, a new well-differentiated gastric endocrine tumor 6 mm in size with a Ki-67 of approximately 2% was detected, and endoscopic ultrasound confirmed it to be limited to the submucosal layer. The patient refused antrectomy and started long-acting somatostatin analog (lanreotide) in 2005 when the Ki-67 index was 7%, but he stopped the treatment after 4 months. In 2007, despite previous endoscopic stability, endoscopic ultrasound showed an infiltrating gastric lesion of 7 cm. At surgery, the disease appeared to be extended to the liver and to the peritoneum (well-differentiated endocrine carcinoma, Ki-67 40%) with both hepatic and massive peritoneal metastases. A regimen of somatostatin analog was soon restarted; however, the disease continued to spread, and the patient died 6 months later. Overall, despite their generally benign course, type 1 gastric carcinoids may have malignant potential, a finding that should be considered when planning the medical workup of these patients.

AB - Gastric carcinoids are rare tumors of the stomach. Gastric carcinoid type 1 is associated with chronic atrophic gastritis, and because of a low metastatic potential, is the most benign type. Death from metastatic disease has been reported in only three patients in a review including 724 cases. The present report refers to a 60-year-old man who was affected by type 2 diabetes mellitus and pernicious anemia and died from metastatic gastric carcinoid type 1. In 1998, a well-differentiated 1.2 cm gastric neuroendocrine tumor, immunoreactive for chromogranin A, with a Ki-67 index less than 2% and with infiltration to the submucosal layer was diagnosed and enucleated. In 2002, a new well-differentiated gastric endocrine tumor 6 mm in size with a Ki-67 of approximately 2% was detected, and endoscopic ultrasound confirmed it to be limited to the submucosal layer. The patient refused antrectomy and started long-acting somatostatin analog (lanreotide) in 2005 when the Ki-67 index was 7%, but he stopped the treatment after 4 months. In 2007, despite previous endoscopic stability, endoscopic ultrasound showed an infiltrating gastric lesion of 7 cm. At surgery, the disease appeared to be extended to the liver and to the peritoneum (well-differentiated endocrine carcinoma, Ki-67 40%) with both hepatic and massive peritoneal metastases. A regimen of somatostatin analog was soon restarted; however, the disease continued to spread, and the patient died 6 months later. Overall, despite their generally benign course, type 1 gastric carcinoids may have malignant potential, a finding that should be considered when planning the medical workup of these patients.

KW - atrophic gastritis

KW - carcinoid metastases

KW - gastric carcinoids

KW - neuroendocrine tumors

KW - octreotide test

UR - http://www.scopus.com/inward/record.url?scp=84859349068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859349068&partnerID=8YFLogxK

U2 - 10.1097/MEG.0b013e328350fae8

DO - 10.1097/MEG.0b013e328350fae8

M3 - Article

C2 - 22465973

AN - SCOPUS:84859349068

VL - 24

SP - 589

EP - 593

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 5

ER -